Andere Sprachen Cantargia AB

Aktien

A2JAZX

SE0006371126

CANTA

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:29:52 18.04.2024			% 5 Tage	% 1. Jan.
3,802 ^SEK	-4,47 %		-10,50 %	+1,71 %

17.04.	Cantargia veröffentlicht neue Daten zum Antikörper Can10, die seine Interaktion mit IL1RAP und seine funktionelle Hemmung detailliert beschreiben	CI
10.04.	Cantargia AB (publ) veröffentlicht präklinische Daten über das Potenzial von CAN10 bei systemischer Sklerose in einer führenden wissenschaftlichen Zeitschrift	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Cantargia publishes Annual Report for 2023	13:31
Notice of annual general meeting in Cantargia AB (publ)	11:01
Cantargia publishes new data on the CAN10 antibody, detailing its interaction with IL1RAP and functional inhibition	17.04.
Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition	17.04.
Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal	10.04.
Cantargia publishes preclinical data on the potential of CAN10 in systemic sclerosis in a leading scientific journal	10.04.
Cantargia AB Presents Unique Effects of Nadunolimab in Pancreatic Cancer	08.04.
Cantargia presents unique effects of nadunolimab in pancreatic cancer	08.04.
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis	02.04.
Cantargia publishes data highlighting the potential of CAN10 in atherosclerosis	02.04.
Cantargia reports progress towards start of DOD-sponsored clinical trial of nadunolimab in leukemia	27.03.
Cantargia AB Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia	27.03.
Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis	14.03.
Cantargia presents new human data further supporting CAN10 in the treatment of systemic sclerosis	14.03.
Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer	05.03.
Cantargia reports new preclinical data on antitumor effects of nadunolimab in pancreatic cancer	05.03.
Cantargia Q4 2023 - Progress with CAN10 and in PDA	23.02.
Cantargia publishes Year-End Report for 2023	22.02.
Cantargia Secures US Approval to Start Patient Recruitment for Pancreatic Cancer Therapy	20.02.
Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab	20.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cantargia AB

Aktien

A2JAZX

SE0006371126

CANTA

Andere Sprachen

Filter